OR WAIT 15 SECS
© 2020 MJH Life Sciences and BioPharm International. All rights reserved.
© 2020 MJH Life Sciences™ and BioPharm International. All rights reserved.
Bio/Pharma companies are galvanized to develop COVID-19 therapies under FDA’s acceleration program.
Recent industry guidance aims to anchor rapid COVID-19 vaccine development in good manufacturing practice protocols.
Automation, digitalization, and supply-chain strategies help mitigate vulnerabilities in both autologous and allogeneic cell therapy manufacturing.
An innovation such as synthetic biology can develop a consistently stable starting cell line for cell therapy source material.